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Table 1
Patient Characteristics
Patient characteristics N¼5
Age 7.5 years (3-11)
Sex (M: F) 4:1
Phase of therapy Induction (week 3-5):4
Delayed Intensiﬁcation: 1
Presenting features Fever: 100%
Seizures: 80%
Altered sensorium: 20%
Preceding focus (100%) Pneumonia: 4
ASOM: 1
Neutropenia (100%) Median duration 16 days (14-23)
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ROLE OF CARDIAC BIOMARKERS IN DETECTION OF MYOCARDIAL
DAMAGE IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ANTHRACYCLINES
Sunil Kumar Singh 1, Rimjhim Sonowal 1, Vikas Agrawal 2, Vineeta
Gupta 1. 1Department of Pediatrics, Institute of Medical Sciences, Banaras
Hindu University, Varanasi, India; 2Department of Cardiology, Institute of
Medical Sciences, Banaras Hindu University, Varanasi, India
Objective: Anthracyclines exposure during treatment of childhood malig-
nancies poses a high risk for development of late cardiotoxicity. Car-
diotoxicity is usually diagnosed when patient is symptomatic with
progressive cardiac dysfunction. Early detection is important to institute
early therapeutic interventions to improve outcome. Aim of present study
was to evaluate cardiac troponin T (cTnT), N-terminal probrain natriuretic
peptide (NT-pro BNP) and creatinine kinase MB isoenzyme (CK-MB) and
echocardiography in the detection of cardiac abnormalities in asymptom-
atic children treated for hematological malignancies with anthracyclines.
Methods: Serum levels of cTnT, NT-pro BNP and CK-MB were measured in
40 survivors (26 males and 14 females) of hematological malignancies (20
high risk acute lymphoblastic leukemia and 20 Hodgkin lymphoma pa-
tients). All patients had received >200 mg/m2 cumulative dose of
anthracyclines and were more than 2 years post chemotherapy. 30 healthy
children were taken as controls. Echocardiography using M-mode and
Doppler measurements were performed on same day as blood in-
vestigations. Study was approved by Institute Ethics committee.
Results: Serum levels of NT-proBNP were signiﬁcantly higher in patients
compared to controls (48.69 ± 20.36 vs 5.08 ± 3.74 pg/ml; p value <0.01). 6
of the patients had left ventricular (LV) dysfunction with mean NT-proBNP
levels of 67.29 ± 22.73 pg/ml which was signiﬁcantly higher than patients
who had normal LV function (mean NT-proBNP levels of 36.19 ± 21.93 pg/
ml. Levels correlated inversely with fractional shortening and ejection
fraction and positively with the cumulative dose of anthracyclines. No
difference was observed between males and females. Serum levels of cTnT
and CK-MB were higher in the patients but they were not statistically
signiﬁcant.
Conclusions: NT-pro-BNP is a sensitive test and correlates with cardiac
function It can be used as a useful biomarker for early detection of
anthracycline cardiotoxicity.TM_SC-1_V1.5
EVALUATION OF SERUM PROCALCITONIN, SERUM INTERLEUKIN-6 AND
INTERLEUKIN-8 TO PREDICT RISK GROUPS IN CHILDREN WITH FEBRILE
NEUTROPENIA AND CANCER
Nuthan Kumar, Fellow 1, Supriya Suresh Gujjar 1, Arathi Srinivasan, Junior
Consultant 2, Padma Keerthiga, Senior Consultant 3, Julius Xavier Scott,
Senior Consultant 4. 1Department of Pediatric Hematology and Oncology,
Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, India;
2Department of Pediatric Hematology and Oncology, Kanchi Kamakoti
Childs Trust Hospital, Chennai, Tamil Nadu, India; 3Department of
Biochemistry, Kanchi Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu,
India; 4Department of Pediatric Hematology and Oncology, Kanchi
Kamakoti Childs Trust Hospital, Chennai, Tamil Nadu, IndiaBackground: Early diagnosis of sepsis in childrenwith febrile neutropenia
remains difﬁcult due to non-speciﬁc clinical and laboratory signs of
infection. There is a need to assess the utility of inﬂammatory markers in
clinical risk assessment for their ability to discriminate between low-risk
and high-risk neutropenic patients since presently there is an insufﬁcient
data to recommend their routine use.
Study design andmethodology: This is a prospective study of children on
therapy admitted with febrile neutropenia between 2015-2016 and
sampled for markers at admission. The febrile neutropenia episodes were
categorized into two groups - Group I:no focus of infection and Group
II:clinically/microbiologically documented infection. Statistical analysis for
comparison were performed using z-test and Receiver operating curves at
various cut-off levels.
Results: A total of 46 episodes of febrile neutropenia were analysed. 76%
were categorized as group I and 24% as group II. The mean value of PCT in
group II was higher (28.07 ng/ml) as compared to group I (1.03ng/ml)
though there was no signiﬁcant statistical difference. At a cut off level of 2
ng/ml for PCT, sensitivity of 63%, speciﬁcity of 91%, PPV of 70%, NPV of 88%
were observed. There was no signiﬁcant difference in the IL-6 and IL-8
levels between both the groups. But at an optimal cut off value of 50 pg/ml,
IL-6 had a NPV of 80% and at a cut off level of 130 pg/ml, IL-8 had a NPV of
73%, however with low sensitivity and speciﬁcity.
Conclusion: IL-6, IL-8 and PCT can be utilized to deﬁne a group of patients
with a low risk of sepsis in view of their favorable NPV. The utility of these
biomarkers together can facilitate early discharge from the hospital, and
the use of oral antimicrobial therapy in turn reducing the cost of therapy
especially in a developing country.
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VITAMIN D STATUS IN NEWLY DIAGNOSED PEDIATRIC ONCOLOGY
PATIENTS AT A TERTIARY CARE HOSPITAL
Purvi Kadakia, Maaz Ahmed, Dhwani Shah, Girish Rajadhyaksha. Department
of Medical Oncology, TNMC & B.Y.L Nair Hospital, India
Introduction: Vitamin D or 25-Hydroxycholecalciferol, an important
immunomodulator, is commonly found to be deﬁcient in healthy young
children as well as in adolescent age group with prevalence of about 50 to
90 % in India. Vitamin D has important anticancer effects such as poten-
tiating apoptosis, prevents proliferation and inhibits angiogenesis. There is
paucity of data on status of vitamin D levels in Pediatric oncology patients
and recently its deﬁciency has been suggested to be associated with can-
cer. Our aim was to study status of vitamin D level in newly diagnosed
Pediatric Oncology patients at a tertiary centre.
Material and Methods: The study included all the newly diagnosed Pe-
diatric oncology cases (solid and hematological neoplasm) between the
age group of 1 to 18 years at a tertiary care centre in a metropolitan city in
India over a period of 12 months from June 2015 to July 2016. The vitamin
D level was done at the time of diagnosis after informed consent from
parents and assent from children above seven years was obtained. Two ml
of fasting blood was collected in a plain bulb which was analysed for 25-
hydroxy cholecalceferol by ELISA method. The age, sex, diagnosis and
vitamin D level at time of diagnosis was recorded in case record form. The
vitamin D level was stratiﬁed as deﬁciency, insufﬁciency, sufﬁciency and
toxicity level as per classiﬁcation by US endocrine society. The data anal-
ysis was done with SSPS software.
Results: Forty one patients were enrolled in the study of which 70.7% were
males. Ten (24.4%) were in the age group of 1 to 5 years, 27 (65.9%)
belonged to 5-14 years and only 4 belonged to 14- 18 years. The study
revealed 32 (78%) children had vitamin D level below 20 ng/dl that is
deﬁcient, 5 (12.19%) patients were between 21- 29 ng/ml indicating
insufﬁciency and only 4 (9.75%) were sufﬁcient which was vitamin D level
more than 30ng/dl. Among 32 deﬁcient patients, nine (28 .4%) were in the
age group of 1 to 5 years, 19 (59.3%) belonged to 5-14 years and 71.1% were
males. Among the subgroup of sufﬁcient vitamin D level, all were males.
Pre B cell acute lymphocyte leukemia (28%) followed by Hodgkin's lym-
phoma (12%) were common malignancies among deﬁcient subgroup.
Conclusion: There is a high prevalence of Vitamin D deﬁciency and
insufﬁciency (90.19%) among Pediatric oncology patients at the time of
diagnosis as described in our cohort. The impact of vitamin D screening
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EFFICACY OF IMMUNIZATION AGAINST HEPATITIS B VIRUS INFECTION
IN ACUTE LYMPHOBLASTIC LEUKEMIA
V.R. Prasanth, Binitha Rajeswari, T. Priyakumary, Parukuttyamma
Kusumakumary. Division of Pediatric Oncology, Regional Cancer Centre,
Thiruvananthapuram, India
Introduction: Children with malignant disease are at an especially high
risk for developing hepatitis B virus infection from immunosuppression
secondary to chemotherapy, radiotherapy andmultiple blood transfusions.
Most of the children infected with HBV develop chronic hepatitis. The
increasing potential for the cure of childhood malignant diseases em-
phasizes the need for a method of reducing hepatitis and its sequelae in
these children.
Objective: The aim of the study was to assess whether immunization
against Hepatitis B (Hepatitis B vaccination +/- Hepatitis B Immunoglob-
ulin) prior to start of chemotherapy provides protective anti HBs titer in
patients with Acute Lymphoblastic Leukemia.
Materials and Methods: This observational study included 104 consecu-
tive children with Acute Lymphoblastic Leukemia treated in Paediatric
Oncology Division, Regional Cancer Centre, Thiruvanathapuram and on
follow up after completion of chemotherapy.The minimum duration of
follow up for inclusion in study was 6 months.The details regarding anti
HBs titers at diagnosis and immunization given were obtained from the
case records.Based on the intial anti HBs titers childrenwere divided into 2
groups, those with protective anti HBs titers (> 10IU/L) and those with
non-protective titers (< 10IU/L).As per the divisions policy, all children
with protective anti HBs titers had received single booster of double dose
of Hepatitis B vaccine.Those with non-protective anti Hbs titers received
HBIG (20IU/Kg ;Max 400IU) followed by double dose of Hepatitis B vaccine
at 0,1,6 months starting 2 months after HBIG. AntiHBsAg titers were done
at follow up using Enzyme Linked Fluoroscent Assay method using VIDAS
(Bio-Merieux).
Results: Of the 104 children included in the study, 67 (64.4%) children had
protective anti HBs titers at presentation, whereas 37 (35.6%) had non-
protective titers. At follow up, 29 (27.8%) children had protective anti HBs
titers and 75 (72.2%) children had non-protective titers (<10 IU/L).Of the 67
children with protective antiHBstitres, 40.2% (n¼27) retained their pro-
tective titers, whereas 59.8% (n¼40) lost their protective titers.In the 37
children with non eprotective antiHBs titers at presentation only 5.4%
(n¼2) developed protective titers following passive and active immuni-
zation, whereas 96.4 % (n¼35) failed to seroconvert.
Discussion: Children receiving chemotherapy even with protective
antiHBs titers at presentation show a loss of protective titers, inspite of
receiving a single booster of double dose HBV vaccine.Those with non-
protective titers, failed to seroconvert despite a combination of passive and
active immunization .The loss of antiHBs titers occurred irrespective of the
levels of initial anti HBs titers larger sample size is required to statistically
validate these results
Conclusion: The loss of protective titers and the failure to seroconvert in
Acute Lymphoblastic Leukemia children receiving chemotherapy is a
concern especially in resource limited settings.The immunization as per this
schedule does not seem to offer protective titres against HBV.There is
probably a need formore frequentmonitoring of antiHBs titers and repeated
administration of Hepatitis B Immunoglobulin as passive prophylaxis which
in developing countries like ours is limited by ﬁnancial constraints.
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VORICONAZOLE PLASMA LEVELS, ITS DETERMINANTS, AND IMPACT ON
OUTCOME OF INVASIVE FUNGAL INFECTIONS IN CHILDREN WITH
CANCER: A PROSPECTIVE STUDY
Vasudeva Bhat, Shripad Banavali, Girish Chinnaswamy, Gaurav
Narula, Tushar Vora, Maya Prasad, Nikita Shah, Brijesh Arora. Tata
Memorial Hospital, Mumbai, IndiaBackground: We evaluated voriconazole plasma levels and determined
the impact of age, dose, route, generic formulations, and concomitant
drugs on plasma levels as well as impact of levels on outcome of invasive
fungal infections (IFI).
Methods: We prospectively studied 256 consecutive children (<19 years)
given voriconazole either for prophylaxis (N-154) or treatment (N-102) of
IFI between August 2008 and February 2016 as per the recommended
doses. IFI diagnosis and clinical outcome evaluation were based on EORTC
Mycoses Study Group (‘EORTC/MSG’) deﬁnitions. The therapeutic range
was deﬁned as 1e5 mg/ml.
Results: A total of 458 voriconazole trough measurements (median age 8
years) were analysed at steady-state [75 on intravenous (IV) and 181 on
oral (PO) doses]. Signiﬁcant Inter- and intrapatient variability in levels was
observed and 46% of patients required dose adjustment. The median vor-
iconazole dose was 16 mg/kg/day and the median duration of therapy was
6 weeks. 53% of children starting with the recommended dose achieved an
adequate trough level and 61% after therapeutic drug monitoring (TDM)-
based dose adjustments. A signiﬁcant correlation between oral doses and
trough levels of voriconazole was observed in patients less than 11 years
old (Spearman's rank correlation coefﬁcient ¼0.18, P < 0.03). A signiﬁcant
relationship was established between plasma levels above normal range
and liver toxicity (P¼0.03). On IV to oral switch, 25% children had drop in
the serum levels to subtherapeutic levels. No impact of gender, steroids
usage, and use of generic formulation was observed on levels or outcome.
Children with Voriconazole level <1 mg /ml were more likely to have
treatment failure at week 6 of voriconazole therapy compared to children
with >1mg/ml (failure, 20.4% vs. 2.1%; P <0.001).). 26% children with sub-
optimal trough levels at 12 hours post voriconazole showed optimal levels
at 8 hours suggesting early plasma clearance and need for frequent dosing.
Conclusions: Our study conﬁrms the large Inter- and intrapatient vari-
ability in voriconazole trough plasma levels particularly after enteral
dosing necessitating higher than recommended doses in young children,
and a trend to non-linear pharmacokinetics in older patients. A signiﬁcant
relationship between voriconazole trough >1 mg/mL and outcomes as well
as some adverse events was conﬁrmed justifying the TDM especially in
young children.
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REGULAR NUTRITIONAL ASSESSMENT OF CHILDREN WITH
MALIGNANCY: OBSERVATIONS OF A NUTRITIONIST DEDICATED TO A
PAEDIATRIC ONCOLOGY UNIT
Syed Anis Fathima, Nutritionist 1, Tarangini Durugappa 2, Anand
Prakash 2. 1Cuddles Foundation, India; 2Department of Paediatrics, Unit of
Hematology e Oncology, St John's Medical College Hospital, Bangalore, India
Abstract
Introduction: Nutritional status is recognised to be amodiﬁable risk factor
for treatment outcomes in Pediatric Oncology. In a developing country
Non- Governmental Organizations can play an important role in sup-
portive care. A Nutritionist supported by Cuddles foundation started
nutritional assessment and intervention at our centre from March 2016.
Objective: To determine the nutritional status in childrenwithmalignancy
at the start of therapy and on serial follow up by a nutritionist dedicated to
the Paediatric Oncology Unit.
Method: All children diagnosed with malignancy between March 2016
and August 2016 were included. Demographic details of children were
collected. Anthropometric indices (Weight, Height, BMI and Mid Upper
Arm Circumference) were recorded at serial time points (at diagnosis and
at follow up visits of 6 to 8 weeks). Counselling of appropriate diet and
enteral based formula feeding were the nutritional interventions. Changes
in nutritional status during this period were analysed.
Results: A total of 27 children were analysed including 15 Haemato-
lymphoid and 12 solid tumors. Mean age of children was 5.6yrs (9 months
to 16 yrs) of which 19 were males and 8 were females. Based on BMI,
21(77.5%) children started therapy with under nutrition including Mild
(-1to -2SD), Moderate (-2 to -3 SD), Severe (<-3SD)malnutrition in 7 (26%),
7 (26%) and 8 (30%) respectively. Two (7.5%) children were overweight at
the start of therapy. On follow up, 46% of children had improvement, 26.9%
were static and 26.9% had a worsening in nutritional status during their
follow up visits. Of 8 (29.6%) children who started with severe
